严格定义免疫耐受期慢性乙肝患者向免疫活动期转变率高:RADICAL联盟队列结果
这项国际多中心队列研究纳入951例严格定义的免疫耐受期慢性乙肝患者,中位随访13年,发现5年、10年、15年内向免疫活动期转变的概率分别为51%、67%、72%,高正常ALT与转变风险增加相关,而显著纤维化和HCC风险较低。
要点
- 免疫耐受期患者5年内超半数转变为免疫活动期,15年累计达72%。
- 基线ALT在20-30 U/L或>30 U/L者向免疫活动期转变风险显著增加。
- 15年显著纤维化风险仅6.3%,HCC风险仅1.1%。
核心结论
- 严格定义的免疫耐受期慢性乙肝患者多数在5年内转变为免疫活动期,高正常ALT者风险最高。
研究设计与样本
- RADICAL联盟国际多中心队列研究,纳入951例严格定义的免疫耐受期慢性乙肝患者,中位年龄33岁,40%为男性,中位随访13年。
主要发现
- 向免疫活动期转变的概率在5年、10年、15年前分别为51%、67%、72%。
- 基线ALT 20-30 U/L者转变风险sHR为1.744(p<0.001),ALT>30 U/L者sHR为3.130(p<0.001)。
- 15年进展为显著纤维化(≥F2)的风险为6.3%,HCC风险为1.1%。
关键数值与推荐
- 免疫耐受期严格定义为基线后第一年持续HBeAg阳性、ALT≤40 U/L、HBV DNA>7 log10 IU/mL且纤维化F0-1。
- 免疫活动期定义为ALT≥50 U/L。
临床怎么用
- 对严格定义的免疫耐受期患者,尤其是基线ALT高正常者,应考虑更频繁监测或抢先治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with immune tolerant (IT) chronic hepatitis B (CHB) have high viral loads, minimal inflammation and minimal fibrosis. Nevertheless, the benign nature of this phase and the need for antiviral therapy remain controversial. OBJECTIVE: We explored the natural history of IT patients by assessing the risk of transition to immune active (IA) disease, fibrosis progression and hepatocellular carcinoma (HCC). DESIGN: This international multicentre study from the RADICAL consortium includes mono-infected patients with CHB from sites around the world. The IT-phase was strictly defined as persistently (1) hepatitis B e-antigen (HBeAg)-positive, (2) alanine aminotransferase (ALT) ≤40 U/L, (3) HBV DNA >7 log10 IU/mL and (4) F0-1 during the first year after baseline. We assessed the probabilities of transition to IA disease (ALT ≥50 U/L), the risk of significant fibrosis (≥F2) and HCC. RESULTS: In total, 951 IT patients were included with a median age of 33, 40% were male with a median follow-up of 13 years. Median ALT and HBV DNA at baseline were 25.5 U/L and 8.4 log10 IU/mL.The probability of transitioning to IA disease was 51%, 67% and 72% before 5 years, 10 years and 15 years. A high-normal ALT was associated with an increased risk of IA disease (subdistribution hazard ratio (sHR): 20-30 U/L: 1.744, p<0.001, sHR: >30U/L: 3.130, p<0.001). IT patients had a low risk of progression to significant fibrosis (15 years: 6.3%), and HCC (15 years: 1.1%). CONCLUSION: The majority of this large cohort of well-defined IT patients transition to IA disease within 5 years of follow-up, with the highest risk observed in those with a high-normal ALT, suggesting that these patients may benefit from either more frequent monitoring or pre-emptive therapy.
引用
- van Velsen LM, Choi WM, Kilany M, et al. High rates of transition to immune active disease in a cohort of strictly defined immune tolerant patients with chronic hepatitis B: results from the RADICAL consortium. Gut. 2026. PMID: 42760116. doi:10.1136/gutjnl-2026-338784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。